Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia

Stephen P. Mulligan, Stephen Opat, Paula Marlton, Bryone Kuss, Poppy Gerungan, Andrea Puig, Marija McGeachie, Constantine S. Tam

Research output: Contribution to journalLetterpeer-review

5 Citations (Scopus)

Abstract

Chemo-immunotherapy and the advent of small molecule inhibitors, including the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib,1 have revolutionised the therapy of chronic lymphocytic leukaemia (CLL). In the original and pivotal RESONATE study, single agent ibrutinib was compared to ofatumumab in patients with relapsed/refractory CLL (R/R CLL), including those with high-risk prognostic factors, and demonstrated superior progression free survival (PFS), overall survival and overall response rate.2

It is recognised that clinical trial populations are highly selected and may not reflect those patients seen in the “real-world” clinical practice where patients are likely to be older and have more comorbidities. Currently, there is limited data with the use of ibrutinib in the general community, both in the Australian context, and from nationally representative datasets...
Original languageEnglish
Pages (from-to)790-793
Number of pages4
JournalBritish Journal of Haematology
Volume198
Issue number4
Early online date14 Jun 2022
DOIs
Publication statusPublished - Aug 2022

Keywords

  • Lymphocytic Leukaemia
  • Ibrutinib
  • Patient outcomes

Fingerprint

Dive into the research topics of 'Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia'. Together they form a unique fingerprint.

Cite this